John Hanna, MD
Neurology · Clemson, SCNPI 1154944569
Payments from drug & device makers
Across 156 payments — averaging $31.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AbbVie$543
- Novartis$292
- AstraZeneca$242
- Neurelis, Inc.$239
- Acadia Pharmaceuticals Inc$228
- plus $2K from 26 others
What the payments were for
- Consulting fees$1,52531%
- Food & beverage$3,37669%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $1,684 |
| AbbVie | 31 | $543 |
| Novartis | 12 | $292 |
| AstraZeneca | 7 | $242 |
| Neurelis, Inc. | 7 | $239 |
| Acadia Pharmaceuticals Inc | 10 | $228 |
| Lundbeck LLC | 10 | $226 |
| Teva Pharmaceuticals USA, Inc. | 12 | $172 |
| Neurocrine Biosciences, Inc. | 8 | $168 |
| CSL Behring | 2 | $137 |
| Argenx US, Inc. | 4 | $106 |
| TG Therapeutics, Inc. | 3 | $102 |
| Amgen | 4 | $86 |
| Grifols USA, LLC | 4 | $85 |
| Eisai Inc. | 3 | $65 |
| Averitas Pharma Inc. | 2 | $61 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Sanofi | 2 | $43 |
| EMD Serono, Inc. | 2 | $41 |
| Novo Nordisk | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Cycle Pharmaceuticals Inc | 2 | $33 |
| Bristol Myers Squibb | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Microvention, Inc. | 1 | $22 |
| Biogen | 1 | $21 |
| Impel Pharmaceuticals LLC | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Merck | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,525
- VALTOCO$122
- ULTOMIRIS$121
- Hizentra$118
- QULIPTA$118
How this compares
$4,901 in reported general payments places this provider in the 65th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 13 | $10,306 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,560 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 20 | $851 |
| Levetiracetam | 17 | $635 |
| Pregabalin | 19 | $406 |
| Gabapentin | 11 | $345 |
| Donepezil Hcl | 11 | $114 |
Paid to pharmacies, not to this prescriber.
Other neurology in Clemson
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
- Katherine RuzhanskyCharleston$1.1M
- Nicholas MilanoCharleston$1.1M
- Howard MandellRock Hill$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.